Thirty-five patients with recurrent and 25 patients with metastatic malignant melanoma after previous radical locoregional surgery were treated with DTIC at the Institute of Oncology in Krakow between 1976 and 1981. Complete and partial remissions were observed in 19/60, i.e., in 31 % of the patients. Our results show an advantage for patients with locoregional recurrence, soft-tissue and lung metastases, provided that the largest deposit is no larger than 5 cm in diameter. There is little chance of remission in patients with liver and bone metastases.
Get full access to this article
View all access options for this article.
References
1.
BackerA.R., KatzH.R.: Cutaneous melanoma. In: Cancer Principles and Practice of Oncology, p. 1124. De VitaV.T.Jr., HellmanS., RosenbergS.A. (eds.), Philadelphia, Toronto, 1982.
2.
BerettaG.: Medical treatment of malignant melanoma.Oncology, 37 suppl.: 88–91, 1980.
3.
ConstanziJ.J., FletcherW.S., BalcerzakS.P., TaylorJ.E., BryanR.M., All-SarrafM., FrankJ.: Combination chemotherapy plus levamisol in treatment of disseminated malignant melanoma.Cancer, 53: 833–836, 1984.
4.
EinhornL.H., BuryessM.A., VallejosL., BodeyG.P., GuttermanJ., MavligitG., HershE.M., LuceJ.K., FreiE., FreireichE.J., GottliebJ.L.: Prognostic correlations and response to treatment in advanced metastatic melanoma.Cancer Res., 34: 1995–2004, 1974.
